Lenrispodun History and Updates

4 events · 2023 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
4
Trial Milestones
0
Pivotal Publications
Lenrispodun — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications2023202420252026Trial: NCT05766813 2023-03-13 → 2025-10-28 (primary completion)today (2026-06-01)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-01Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Lenrispodun since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Past events

2025
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05766813
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05766813
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
2023
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT05766813
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.